Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
Navid Shomali, Marwah Suliman Maashi, Behzad Baradaran, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20

Showing 20 citing articles:

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 102
Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
Amirhossein Mardi, Anastasia V. Shirokova, Rebar N. Mohammed, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 56
Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment
Nadia Ghasemi Darestani, Anna I. Gilmanova, Moaed E. Al‐Gazally, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 37
Current status of skin cancers with a focus on immunology and immunotherapy
Mahsa Khayyati Kohnehshahri, Aila Sarkesh, Leila Mohamed Khosroshahi, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 35
CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Shunshun Bao, Mohammad Darvishi, Ali H. Amin, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 7945-7968
Closed Access | Times Cited: 18
miR-142-3p encapsulated in T lymphocyte-derived tissue small extracellular vesicles induces Treg function defect and thyrocyte destruction in Hashimoto’s thyroiditis
Genpeng Li, Linye He, Jing Huang, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 18
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Ali Keshavarz, Ali Salehi, Setareh Khosravi, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target
Xianlong Fang, Xue-ping Cao, Jun Xiao, et al.
Journal of drug targeting (2024) Vol. 32, Iss. 3, pp. 223-240
Closed Access | Times Cited: 5
The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies
Min Yang, Ying Zhang, Min Li, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
MicroRNAs as novel biomarkers and potential therapeutic options for inflammatory cardiomyopathy
Ganna Aleshcheva, Christian Baumeier, Dominik Harms, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3410-3418
Open Access | Times Cited: 9
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme
Amin Daei Sorkhabi, Aila Sarkesh, Hossein Saeedi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 14
Survivin; a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis
Navid Shomali, Behzad Baradaran, Amin Daei Sorkhabi, et al.
Gene (2022) Vol. 844, pp. 146829-146829
Closed Access | Times Cited: 11
Contribution of survivin to the immune system, allergies and autoimmune diseases
Abdollah Jafarzadeh, Nasrin Bazargan, Nazanin Chatrabnous, et al.
Human Immunology (2023) Vol. 84, Iss. 4, pp. 301-310
Closed Access | Times Cited: 6
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
Zahra Sabahi, Amin Daei Sorkhabi, Aila Sarkesh, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110266-110266
Closed Access | Times Cited: 5
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
Amin Daei Sorkhabi, Erfan Komijani, Aila Sarkesh, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
MicroRNA-155 acts as a potential prognostic and diagnostic factor in patients with ankylosing spondylitis by modulating SOCS3
Mohammadsaleh Jahangir, Mohammad Saeed Kahrizi, Mohammad Natami, et al.
Molecular Biology Reports (2022) Vol. 50, Iss. 1, pp. 553-563
Closed Access | Times Cited: 3
Evaluation of survivin expression and regulating miRNAs of survivin expression in peripheral blood mononuclear cells in systemic lupus erythematous patients
Nasim Bolouri, Reza Mansouri, Elham Farhadi, et al.
Lupus (2024) Vol. 33, Iss. 11, pp. 1203-1211
Closed Access
Oleuropein as An Effective Suppressor of Inflammation and MicroRNA-146a Expression in Patients with Rheumatoid Arthritis.
Hanieh Mahi, Zahra Yousefi, Fatemeh Toufan, et al.
PubMed (2023) Vol. 25, Iss. 7, pp. 505-512
Closed Access | Times Cited: 1
The Behaviour of Serum Survivin in Patients With Lupus Nephritis
Renata Valente Lisboa, Fabíola Reis de Oliveira, Thaíse Oliveira Quaresma, et al.
Biomarker Insights (2022) Vol. 17
Open Access | Times Cited: 1
Restoration of miR-200c sensitizes breast cancer cells to cytarabine
Mahsa Maleki Moghaddam, Elham Baghbani, Hadi Alizadeh, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top